Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2020-03-27

FDA Approved: SEROQUEL XR — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

FDA approved a supplemental application for SEROQUEL XR (quetiapine) from AstraZeneca, resulting in labeling updates for the drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SEROQUEL XR (Quetiapine)

Snippet

SUPPL AP for SEROQUEL XR (QUETIAPINE)